Skip to main content

22-05-2018 | Gout | Editorial | Article

Audits on gout management: Far from excellence, but working on it

Fernando Pérez-Ruiz

It would be desirable for excellent gout management to be common practice within the specialist rheumatology setting. But achieving excellent practice may require complex, time-consuming procedures that may be limited within the tight daily agenda of visits, especially in public health settings. This may be interpreted as a lack of interest in gout by specialists compared with other systemic diseases, such as rheumatoid arthritis (RA).

However, a recent audit of RA management [1] demonstrated that around 40% of patients did not show any meaningful improvement of DAS28 scores after 3 months of disease management by specialists, showing that the management of RA was also unsatisfactory.

Therefore, the explanation that gout is not specifically perceived as an important field of specialty for rheumatologists, resulting in lack of proper management of the disease, cannot be sustained. Audits of other diseases such as RA show that management of these conditions is far from excellent, despite being perceived as being of the utmost importance in rheumatology practice.

A recent paper by Roddy et al [2] has reported the results of an audit of gout management in the rheumatology setting, compared with the EULAR 2006 recommendations and BSR 2007 guidelines. This report found that the diagnostic gold standard of presence of monosodium urate (MSU) crystals occurred in just 13% of cases, whereas urate lowering therapy (ULT) was prescribed or continued in 76% of patients. The authors also found that prophylaxis, which was prescribed in over 90% of patients starting ULT, was most effective in achieving target serum uric acid (sUA) levels of < 6 mg/dL or 0.36 mmol/L.

The majority of gout patients are managed by primary care (PC) teams. Management of gout in PC has been associated with low rate of initiation of urate-lowering treatment and scarce achievement of target therapeutic sUA levels [3]. Indeed, in a nationwide study in the UK, the median rate of patients with gout prescribed ULT was 32.5%, but ranged from 0% to 100% depending on the clinical practice [4].

Control of sUA levels have even worsened over time in some studies [5]. In New Zealand, where gout is very prevalent, less than half of patients admitted to hospital or with prolonged stay due to a gout flare were on ULT, and of those on ULT, less than half had been tested for sUA [6]. Worse than that, after admission for gout as primary diagnosis, of those patients who were not on ULT, less than one third were prescribed ULT while at hospital or recommended for prescription after discharge [7].

One would expect a different landscape in countries that have developed a highly efficient and universal healthcare system. On the contrary, an increase in rates of hospital admission, duration of stay, and therefore costs have been reported recently to have occurred in Sweden [8]. The report showed that less than one third of patients admitted had been on ULT during the previous 6-month period, with prescriptions being mostly associated with the presence of severe comorbidities [9]. Similar figures have also been reported from other developed countries.

Audits may show areas for improvement. Similar results to those reported by Roddy et al were also observed some years ago in a Spanish national audit [10], where the rate of crystal-based diagnosis was 26% and the rate of patients achieving sUA target levels of < 6 mg/dL was only 42%. A second, follow-up audit disclosed a 50% improvement during a 6-year period, with over two thirds reaching sUA target levels. However, the advent of febuxostat may have helped with this improvement, as clinical inertia in increasing medication dosage or switching medication was persistent [11].

A proof-of-concept study [12] has shown that nurse support has helped in achieving close to excellent results in the management of gout. Furthermore, a striking improvement in the management of gout was observed after implementing the use of electronic templates in patients’ files [13]. The rates of sUA testing and achieving sUA target levels in a primary setting doubled in a few months.

Although the reasons why gout is not well managed are not known for certain, it has been suggested that an incorrect perception that gout is a self-inflicted disease induced by overindulgent attitudes towards lifestyle has resulted in scarce academic interest compared with other serious and life-threatening systemic conditions, and lack of awareness that gout is one of the few “curable” rheumatologic conditions [14]. Preference of rheumatologists to dedicate most of their time-limited efforts to treating the most “serious” diseases may also contribute. Education at all levels, including among the general population, academics, physicians, and patients, may help to improve management in the long-term.

We cannot, as specialists, honestly intend to lead science and practice when audits reflect that we are still far from excellent. Increase in awareness due to the appearance of new medications, education to improve adherence, and even electronic templates for management may all help to improve the management of gout. General practitioners may mirror or copy attitudes and procedures observed in specialists, therefore it is much better for patients if rheumatologists follow excellent practice as closely as possible.

About the author

Fernando Pérez-Ruiz

Fernando Pérez-Ruiz is Chief of the Rheumatology Division, Cruces University Hospital, Head of the Investigation Group for Arthritis at BioCruces Health Research Institute, and Associated Professor of the Department of Medicine in the Basque Country University in Vizcaya, Spain. Disclosures

Full biography


Related topics

Related content

24-05-2017 | Gout | Editorial | Article

Taking gout seriously

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits